Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women
This study has been completed.
Study NCT00074425 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: December 11, 2003 Last Updated: October 28, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Communicable Diseases
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
BufferGel
PRO 2000/5 Gel
Placebo gel
Additional drug interventions recognized in this trial
Anti-Infective Agents, Local
More general drug interventions related to this trial
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
HIV Prevention Trials Network
Back to top of Main Content
